13/09/2017 22:32:26

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

SANTA CLARA, Calif., 2017-09-13 23:32 CEST (GLOBE NEWSWIRE) --

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that their integrated oncology platform has facilitated the preclinical development of a HERA-GITRL immunotherapeutic from Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Cancer.

The data derived from studies using CrownBio’s portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy testing.

“CrownBio’s integrated oncology platform confirmed our agent’s efficacy in NSCLC and head and neck cancers,” said Dr. Mauricio Redondo Müller, Director, Preclinical Development at Apogenix. “The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage.”

“It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area.”

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.

         Media Enquiries:

         

         Jody Barbeau

         

         Crown Bioscience Inc. marketing@crownbio.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Sep
 
  Jeg forstår ikke, at EI tillader en skribent som Baronen84, at forpeste hele forummet med løgn, hå..
46
15 Sep
BAVA
FUCK, hvor er disse to usympatiske individer belastende. Ved godt jeg ikke burde starte denne tråd, ..
36
18 Sep
FING-B
Goodwrench, sikke en omgang vrøvl.   Det er ikke kun hyklerisk, men også dybt patetisk, når du komme..
34
15 Sep
BAVA
Jeg tillader mig at starter en ny tråd med det som jeg har skrevet tidligere til den hån Baron84 har..
33
15 Sep
BAVA
Har vel tabt omkring 225K men det er ikke det værste. Det værste er at der så stadig ikke er en orde..
29
16 Sep
BAVA
Personligt vil jeg jo sige, at nu er der det gode til BN tilbage, så hvis man fik en over snuden så ..
26
16 Sep
BAVA
Først - surt show - been there, done that - så kender følelsen! Har set mange som har skrevet - at ..
22
19 Sep
PNDORA
Her er min model ;)      
21
17 Sep
 
er højt i kurs her  .   Det er synd, at voksne mennesker ikke har mere pli, så snart de er anonyme .
18
16 Sep
BAVA
Kære EnKommentar   Ja, det var noget af en lussing, men vi har faktisk siddet med data, uden rigtigt..
17

Form 8.5 (EPT/RI) - Booker Group Plc

20/09/2017 08:10:36
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Alliance Trust PLC : Transaction in Own Shares

20/09/2017 07:00:12
20 September 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 19 September 2017 the Company purchased for cancellation 87,404 ordinary shares of 2.5p each at a price of 709.0159p per share.  Therefore, the total number of voting rights in the Company is now 349,689,651.    The above figure (349,689,651) may be used by sh..

Novae Group plc: Announcement of Regulatory Approvals

19/09/2017 14:28:44
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 19 September 2017 RECOMMENDED CASH ACQUISITION of NOVAE GROUP PLC by AXIS SPECIALTY UK HOLDINGS LIMITED (a wholly-owned subsidiar..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
TRANSDIGM GROUP SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against TransDigm Group Incorporated - (TDG)
2
Marcum LLP and Connecticut Technology Council Announce 2017 Marcum Tech Top 40 Winners; Stamford’s MediaCrossing, Inc. Named Connecticut’s Fastest Growing Technology Company
3
Milost Global Announces Formation of a New Africa Buyout Fund
4
Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
5
TINTRI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tintri, Inc. To Contact The Firm

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 September 2017 12:15:57
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20170919.1 - EUROWEB3 - 2017-09-20 13:15:57 - 2017-09-20 12:15:57 - 1000 - Website: OKAY